GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $886,521.44 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 12,019 shares of GeneDx stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44. Following the transaction, the chief financial officer now directly owns 32,932 shares of the company’s stock, valued at $2,429,064.32. The trade was a 26.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Stock Performance

Shares of WGS stock opened at $79.43 on Thursday. The stock has a market cap of $2.18 billion, a PE ratio of -25.58 and a beta of 2.11. GeneDx Holdings Corp. has a 52-week low of $1.45 and a 52-week high of $89.11. The business has a 50-day simple moving average of $61.33 and a 200-day simple moving average of $40.68. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. During the same quarter last year, the company earned ($0.82) EPS. The business’s revenue was up 44.3% on a year-over-year basis. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently modified their holdings of WGS. Acadian Asset Management LLC acquired a new position in GeneDx in the 2nd quarter worth about $34,000. nVerses Capital LLC purchased a new position in shares of GeneDx during the 2nd quarter valued at approximately $50,000. CWM LLC acquired a new stake in GeneDx in the 3rd quarter valued at $89,000. SG Americas Securities LLC purchased a new stake in GeneDx in the 3rd quarter worth $198,000. Finally, Point72 DIFC Ltd purchased a new position in GeneDx during the third quarter valued at $220,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

WGS has been the subject of several research reports. The Goldman Sachs Group upped their target price on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company boosted their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. BTIG Research upped their price target on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, TD Cowen raised their target price on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.